The progress in classification and prognosis evaluation of BCR::ABL1 positive acute lymphoblastic leukemia
10.3760/cma.j.cn121090-20240315-00096
- VernacularTitle:BCR::ABL1阳性急性B淋巴细胞白血病分型与预后评估进展
- Author:
Yuchen YAN
1
;
Cheng WANG
;
Jianqing MI
;
Jin WANG
Author Information
1. 上海交通大学医学院附属瑞金医院血液内科，上海 200025
- From:
Chinese Journal of Hematology
2024;45(7):705-710
- CountryChina
- Language:Chinese
-
Abstract:
The application of tyrosine kinase inhibitors and targeted immunotherapy has revolutionized the therapeutic strategies and clinical outcome for BCR::ABL1-positive B-cell acute lymphoblastic leukemia (BCR::ABL1 + B-ALL). The classification was updated successively by the World Health Organization and the International Consensus Classification in 2022. The risk stratification of this entity, for the first time, was modified by the National Comprehensive Cancer Network in 2023, both minimal residual disease assessment and IKZF1 plus genotyping recognized as critical prognostic factors. These important updates would have significant implications for clinical management. Therefore, this review focused on the latest advances in the classification and prognostic evaluation of BCR::ABL1 + B-ALL.
